A preclinical program stalls before the science starts. Outsourced preclinical studies now move through contract research organizations, specialized labs, and functional service providers that each need to be qualified, contracted, and paid before a single sample moves. The molecule is ready. The operating model around it usually is lagging behind.
Procurement leaders feel this as a strange gap. Sourcing the right lab takes days. Getting to a started study takes months. The time disappears into the space between choosing a supplier and beginning, a space filled with regulated qualification and contract steps that repeat with every new engagement. For R&D teams running outsourced portfolios, this pattern is familiar.
Sourcing the right lab takes days. Starting the actual study takes months. Here's why the delay is almost never about the science.Most teams assume delay lives in the science. But it usually lives in the setup. A single engagement can require:
Each step is owned by a different function, tracked in a different system, and started from zero.
Now multiply that by a growing portfolio. Ten studies across three business units means ten separate setups. The friction compounds rather than flattening. That's why adding outsourced capacity often slows a team down before it speeds anything up, and why cycle time predicts program timelines more reliably than sourcing speed does.
Q: What causes the longest delays in outsourced preclinical studies?
A: The delays sit in the steps before work begins. Confidentiality agreements, master services agreements, study-specific scoping, and supplier qualification usually run as separate manual steps across different teams. Science Exchange connects those steps into one flow, so a new engagement starts from prior context instead of restarting the full setup for every study.
Qualification is the step buyers underestimate most. Confirming a lab can perform regulated nonclinical work is a recurring obligation. The evidence has to be current, study-specific, and defensible in an audit years later. When that evidence lives in a spreadsheet or a shared drive, it ages the moment it is filed. Audit-ready systems handle this differently; Science Exchange's compliance infrastructure was built around that requirement.
So the next study restarts the review. The same lab gets re-qualified because nobody trusts the last record to still be valid. This is the exact problem "What Procurement Owns When Science Is the Risk" named: qualification evidence is procurement's to carry. Carrying it by hand is where scaling breaks.
Q: How does Science Exchange keep supplier qualification current across studies?
A: Science Exchange holds qualification, contract structures, and compliance context in one place and carries them forward. When a qualified lab is used again, the second study builds on the first record rather than repeating the review. That is the difference between tracking a supplier and keeping that supplier ready for the next regulated engagement. See the platform.
Speed has a quiet trade-off. The fastest way to start a study is to reuse the lab you already know. Over time a program leans on a handful of irreplaceable vendors, and that concentration becomes its own risk. If one lab hits capacity or loses a certification, the studies riding on it wait.
Maintaining reproducibility is another key factor. When setups are rushed and workloads become highly concentrated, study quality degrades in ways that only surface later in the process. Freedman, Cockburn, and Simcoe estimated that roughly $28 billion per year is spent on irreproducible preclinical research in the US alone (PLOS Biology, 2015). Broadening the qualified network is safer, but only if adding a new supplier doesn't reset the clock.
More CRO relationships shouldn't mean more onboarding headaches. There's a smarter way to scale outsourced R&D without adding risk.Q: Does using more preclinical suppliers slow procurement down?
A: It does when every new supplier means a full manual onboarding. Qualification and contracting that run through shared infrastructure eliminate that penalty. Science Exchange gives teams access to thousands of pre-qualified suppliers under one contract and one payment structure, so widening the network to reduce concentration risk does not add a new setup cycle each time.
The winning move is to stop treating each study as a fresh transaction. Setup work that repeats can be built once and carried forward: one contract structure, one qualification standard, one payment entity. The regulated requirements don't go away, but they are out of the way. Why? They stop being re-created from scratch on every single engagement.
This is where the numbers matter, and where they need internal sign-off. Science Exchange reports supplier onboarding running roughly 6.5x faster through purpose-built infrastructure, alongside a contracting cycle reduction of more than 50% against the disconnected baseline. For a scientist waiting to start, that is the difference between this month and next quarter.
For teams past a handful of studies, the question is no longer which lab to pick. It is whether the operating model can absorb more studies without more manual work. That is the layer Science Exchange was built for.
Q: Should we evaluate Science Exchange if our preclinical outsourcing is already growing?
A: Yes, if adding studies keeps adding setup work. Science Exchange is intelligent infrastructure for science, built for regulated R&D: audit-ready qualification, contract and payment structures that carry forward, and one network of pre-qualified suppliers. It is designed so a growing portfolio starts studies faster and stays compliant. See how teams run external R&D on the platform.
The questions to ask your own team are simple.
How long is the gap between picking a supplier and starting the work? How much of that time is spent repeating setup work you could have done once?
The science should never be the thing that waits.